Retatrutide vs Semaglutide: Research Comparison (UK 2026)

At a glance

Property	Retatrutide	Semaglutide
Receptor profile	Triple GIP / GLP-1 / glucagon	GLP-1 monoagonist
Developer	Eli Lilly	Novo Nordisk
UK regulatory status	Not approved — research only	MHRA-licensed (Wegovy 2.4 mg — obesity; Ozempic — T2D)
Mean weight reduction	≈24% at 48 weeks (Phase 2, 12 mg)	≈15% at 68 weeks (STEP-1, 2.4 mg)
Dosing frequency	Once weekly SC injection	Once weekly SC injection
Half-life	≈6 days	≈7 days
Glycaemic control	Robust reduction in Phase 2 (T2D sub-group)	Robust HbA1c reduction; SURPASS programme
Cardiovascular outcome data	None published (Phase 3 ongoing)	SELECT trial: 20% MACE reduction (obesity, no T2D)
Notable side-effect signal	GI + modest heart-rate increase (Phase 2)	GI (nausea/diarrhoea); gallbladder events

Receptor pharmacology

Semaglutide is a selective GLP-1 receptor agonist with 94% amino acid homology to native human GLP-1, modified at positions 8 and 34 to resist dipeptidyl peptidase-4 degradation. A C18 fatty-diacid chain tethered via a linker to lysine at position 26 provides high-affinity albumin binding, extending the half-life to approximately seven days and permitting once-weekly subcutaneous dosing. Its mechanism is essentially a prolonged amplification of the endogenous GLP-1 signal: enhanced glucose-dependent insulin secretion, suppressed glucagon, slowed gastric emptying, and central appetite reduction via hypothalamic and brainstem GLP-1 receptors.

Retatrutide extends this receptor engagement to three axes simultaneously. Its GIP receptor activity broadly parallels that of tirzepatide; the critical additional feature is glucagon receptor agonism. Hepatic glucagon signalling drives glycogenolysis and increases hepatic glucose output under fasting conditions, but in the context of a concurrent strong incretin signal (preventing net hyperglycaemia), the energy-expenditure and lipolytic effects of glucagon are unmasked. The theoretical result is a compound that reduces caloric intake via GLP-1/GIP pathways whilst simultaneously increasing caloric expenditure via glucagon — a dual-sided attack on energy balance that semaglutide's single-receptor mechanism cannot replicate.

Clinical evidence base

Semaglutide 2.4 mg carries one of the most robust obesity evidence packages in modern pharmacology. The STEP programme encompasses four pivotal trials: STEP-1 (Wilding et al., NEJM 2021; n = 1,961 without T2D) reported 14.9% mean weight loss at 68 weeks; STEP-2 assessed T2D; STEP-3 combined semaglutide with intensive behavioural intervention; STEP-4 demonstrated weight regain on discontinuation. The SELECT trial (2023; n = 17,604) extended the evidence to cardiovascular outcomes, showing a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes — a landmark result that directly informed expanded MHRA and EMA indications.

Retatrutide's evidence base rests primarily on one Phase 2 trial (Jastreboff et al., NEJM 2023; n = 338) spanning 48 weeks. The 12 mg arm recorded approximately 24.2% mean weight reduction — numerically superior to any published semaglutide dataset — but derived from a far smaller sample, a shorter duration, and without the cardiovascular or longer-term safety follow-up that characterises the STEP programme. The Phase 3 TRIUMPH programme (TRIUMPH-1 through -4) was initiated in 2023; head-to-head data versus semaglutide or tirzepatide is not yet available.

Safety signals

Semaglutide's post-marketing safety profile is now the most comprehensively characterised in the GLP-1 class. Beyond the expected gastrointestinal events, the STEP and SUSTAIN programmes identified a modest increase in gallbladder-related events (cholelithiasis, cholecystitis) and, as with all GLP-1 agonists, a class warning for thyroid C-cell tumours based on rodent carcinogenicity studies. The SELECT trial added important reassurance on cardiovascular safety in a high-risk population.

The retatrutide Phase 2 trial reported a small but consistent heart-rate increase of 3–6 bpm in the higher-dose arms, an effect not observed with semaglutide and likely attributable to glucagon receptor agonism. Whether this signal persists, attenuates, or has clinical significance in a Phase 3 population remains to be determined. The GI adverse event profile was broadly similar between arms.

Which to prioritise for research

For researchers contextualising the GLP-1 class in 2026, semaglutide provides the reference dataset: two regulatory approvals from the MHRA, positive cardiovascular outcomes data, and the largest post-marketing surveillance base of any injectable GLP-1 agent. Retatrutide is the appropriate compound to study when the research question concerns what lies beyond current GLP-1 pharmacology — specifically whether glucagon co-agonism provides additive metabolic benefit over dual GIP/GLP-1, or over GLP-1 alone. Mechanistic investigators comparing energy-expenditure pathways will find this the most instructive pairing; clinical translation researchers should note the substantial asymmetry in evidence maturity and regulatory standing.